Health & Safety Industry Today

Europe Cell and Gene Therapy Market to Hit $15.15 Billion by 2028 - Exclusive Focus Research Report by Arizton

Get this Report for Lesser With Our Subscription Services
Published 30 April 2024

According to Arizton's latest focus report the Europe cell & gene therapy market is growing at a CAGR of 38.20% during 2022-2028.

To Know More, Click:

The cell & gene therapy market in Europe is growing gradually due to the presence of advanced healthcare infrastructure, high acceptance of cell & gene therapies, and high per capita healthcare expenditure in various developed countries of Europe. The market in Europe is witnessing steady growth due to higher funding from public and private institutes. Support from regulatory bodies for product approvals and providing fast-track designations of products encourage vendors to hasten manufacturing.

Italy and Germany are introducing innovative payment methods for expensive cell & gene therapy products in the market, thus motivating patients to opt for advanced medical products such as cell therapy and gene therapy. In addition to sophisticated healthcare infrastructure, healthcare spending in Europe is high, which will favor the market growth during the forecast period.

Key Highlights:

·        In December 2022, uniQure and its partner CSL received a positive opinion recommending conditional marketing authorization (CMA) from CHMP for etranacogene dezaparvovec for the treatment of adults with hemophilia B.

·        Myrtelle announced that the European Medicines Agency (EMA) granted orphan drug (OD) designation for rAAV-Olig001-ASPA for the treatment of Canavan disease.

·        In December 2022, Kite, a Gilead Company, and Tmunity Therapeutics (Tmunity) announced that the companies signed an agreement in which Kite would acquire Tmunity. The acquisition will provide Kite with pre-clinical and clinical programs, including an ‘armored’ CAR T technology platform.

·        In October 2022, French companies formed a strategic alliance to cover cell & gene therapy (C>) GMP manufacturing.

Why Should You Buy this Report?

Develop and design your in-licensing and out-licensing strategies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the Europe cell and gene therapy market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for strategic partnerships.

Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.

To Know More, Click:

Market Segmentation

  • Product Type

                   ▪ Cell therapy

                   ▪ Gene therapy

  • Application type
  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others
  • End-user type
  • Hospitals
  • Cancer Care Centers
  • Others

Gene Therapy Vendors


Gilead Sciences 



Orchard Therapeutics 

BioMarin Pharmaceutical (BioMarin) 

PTC Therapeutics

Bristol-Myers Squibb (BMS)

Legend Biotech 

bluebird bio 

Human Stem Cells Institute PJSC (HSCI) 

Cell Therapy Vendors


Smith & Nephew 

CHIESI Farmaceutici



Takeda Pharmaceutical Company 




Key Emerging Investigational Vendors

Adaptimmune Therapeutics

AgenTus Therapeutics

Autolus Therapeutics



CombiGene AB


FREELINE Therapeutics


Psioxus Therapeutics

Sparing Vision


About Focused Reports by Arizton    

Welcome to Focused Reports, an esteemed Arizton Advisory & Intelligence subsidiary committed to delivering precise and insightful market research reports across all key geographies. Our unique selling proposition lies in our affordable pricing, accurate data, in-depth research, and presentation-ready reports. With us, expensive market research is a thing of the past. We aim to be strategic, providing valuable data. Focus Reports is where folks come to name their ideas, create a compelling brand and a great-looking website, and attract customers with digital and social marketing.     

Contact Us:    

Call: +1-312-235-2040                                               

          +1 302 469 0707                                              



Other Industry News

Ready to start publishing

Sign Up today!